These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21384511)

  • 1. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.
    Eurich D; Boas-Knoop S; Ruehl M; Schulz M; Carrillo ED; Berg T; Neuhaus R; Neuhaus P; Neumann UP; Bahra M
    Liver Transpl; 2011 Mar; 17(3):289-98. PubMed ID: 21384511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes?
    McCaughan GW; Shackel NA; Bowen DG
    Liver Transpl; 2011 Mar; 17(3):219-21. PubMed ID: 21384503
    [No Abstract]   [Full Text] [Related]  

  • 4. Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used.
    Bitetto D; Fabris C; Falleti E; Fornasiere E; Avellini C; Cmet S; Cussigh A; Fontanini E; Pirisi M; Corradini SG; Merli M; Molinaro A; Toniutto P
    Transplantation; 2012 May; 93(10):1038-44. PubMed ID: 22495472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy.
    Eurich D; Boas-Knoop S; Bahra M; Neuhaus R; Somasundaram R; Neuhaus P; Neumann U; Seehofer D
    Transplantation; 2012 Mar; 93(6):644-9. PubMed ID: 22411462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
    Eurich D; Neumann UP; Boas-Knoop S; Neuhaus R; Kiessling A; Yahyazadeh A; Trautwein C; Wasmuth H; Puhl G; Neuhaus P; Bahra M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):153-60. PubMed ID: 22989351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
    Firpi RJ; Dong H; Clark VC; Soldevila-Pico C; Morelli G; Cabrera R; Norkina O; Shuster JJ; Nelson DR; Liu C
    Liver Int; 2013 Jan; 33(1):72-8. PubMed ID: 23107586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation.
    Graziadei IW; Zoller HM; Schloegl A; Nachbaur K; Pfeiffer KP; Mark W; Mikuz G; Pratschke J; Margreiter R; Vogel W
    Liver Transpl; 2012 Jun; 18(6):671-9. PubMed ID: 22298465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-28B polymorphism in hepatitis C and liver transplantation.
    Duarte-Rojo A; Deneke MG; Charlton MR
    Liver Transpl; 2013 Jan; 19(1):49-58. PubMed ID: 23008132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 3 L412F polymorphism may protect against acute graft rejection in adult patients undergoing liver transplantation for hepatitis C-related cirrhosis.
    Citores MJ; Baños I; Noblejas A; Rosado S; Castejon R; Cuervas-Mons V
    Transplant Proc; 2011; 43(6):2224-6. PubMed ID: 21839239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease.
    Eurich D; Boas-Knoop S; Struecker B; Neuhaus R; Neuhaus P; Bahra M
    Transplantation; 2013 Jan; 95(1):203-8. PubMed ID: 23202532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
    Ackefors M; Nyström J; Wernerson A; Gjertsen H; Sönnerborg A; Weiland O
    J Viral Hepat; 2013 Nov; 20(11):770-8. PubMed ID: 24168256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation.
    Joshi D; Salehi S; Brereton H; Arno M; Quaglia A; Heaton N; O'Grady J; Agarwal K; Aluvihare V
    Liver Transpl; 2013 Apr; 19(4):383-94. PubMed ID: 23408392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
    Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
    Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.